Video below is from Anteo Diagnostics's VP of Scientfic Affairs Josh Soldo who presented this presentation at AACC late July.
This sample pre treatment opportunity is one of the areas Anteo is working with that I personally consider a massive opportunity.
AN ESTIMATED 7 TO 10 BILLION LABORATORY TESTS ARE PERFORMED EACH YEAR IN THE UNITED STATES ALONE. LABORATORY TEST RESULTS INFLUENCE APPROXIMATELY 70% OF MEDICAL DECISIONS.
THERE IS A NEED FOR A SIMPLE, INEXPENSIVE, AUTOMATABLE AND EFFECTIVE SOLUTION TO MITIGATE SAMPLE SPECIFIC INTERFERENCES WITHOUT ALTERING OR CHANGING THE SAMPLE COMPOSITION. IN THE U.S. ALONE UP TO 10 BILLION LABORATORY TESTS ARE PERFORMED EACH YEAR, AND THE GLOBAL IMMUNOASSAY INSTRUMENTS AND REAGENTS MARKET IS EXPECTED TO REACH $19.1 BILLION BY 2018.
I spoke about this presentation in a earlier blog post :
A couple of big nuggets in this presentation - Josh mentions a partnership to be announced with a US reference laboratory late August/ Early September.
DISCLOSURE : THE AUTHOR HOLDS SHARES IN THIS COMPANY. THIS RESEARCH IS NOT A RECOMMENDATION TO BUY OR SELL SHARES IN THIS COMPANY. THE AUTHOR MAY AT ANY TIME BUY OR SELL SHARES WITHOUT NOTICE. PLEASE DO YOUR OWN RESEARCH